{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T13:02:24Z","timestamp":1758632544038},"reference-count":51,"publisher":"American Society for Microbiology","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin. Vaccine Immunol."],"published-print":{"date-parts":[[2014,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>New prevention and treatment strategies are needed for visceral leishmaniasis, particularly ones that can be deployed simply and inexpensively in areas where leishmaniasis is endemic. Synthetic molecules that activate Toll-like receptor 7 and 8 (TLR7\/8) pathways have previously been demonstrated to enhance protection against cutaneous leishmaniasis. We initially sought to determine whether the TLR7\/8-activating molecule resiquimod might serve as an effective vaccine adjuvant targeting visceral leishmaniasis caused by infection with<jats:named-content content-type=\"genus-species\">Leishmania infantum chagasi<\/jats:named-content>. Resiquimod was topically applied to the skin of mice either prior to or after systemic infection with<jats:named-content content-type=\"genus-species\">L. infantum chagasi<\/jats:named-content>, and parasite burdens were assessed. Surprisingly, topical resiquimod application alone, in the absence of vaccination, conferred robust resistance to mice against future intravenous challenge with virulent<jats:named-content content-type=\"genus-species\">L. infantum chagasi<\/jats:named-content>. This protection against<jats:named-content content-type=\"genus-species\">L. infantum chagasi<\/jats:named-content>infection persisted as long as 8 weeks after the final topical resiquimod treatment. In addition, in mice with existing infections, therapeutic treatment with topical resiquimod led to significantly lower visceral parasite loads. Resiquimod increased trafficking of leukocytes, including B cells, CD4<jats:sup>+<\/jats:sup>and CD8<jats:sup>+<\/jats:sup>T cells, dendritic cells, macrophages, and granulocytes, in livers and spleens, which are the key target organs of visceralizing infection. We conclude that topical resiquimod leads to systemic immune modulation and confers durable protection against visceralizing<jats:named-content content-type=\"genus-species\">L. infantum chagasi<\/jats:named-content>infection, in both prophylactic and therapeutic settings. These studies support continued studies of TLR-modulating agents to determine mechanisms of protection and also provide a rationale for translational development of a critically needed, novel class of topical, preventative, and therapeutic agents for these lethal infections.<\/jats:p>","DOI":"10.1128\/cvi.00338-14","type":"journal-article","created":{"date-parts":[[2014,7,17]],"date-time":"2014-07-17T04:21:14Z","timestamp":1405570874000},"page":"1314-1322","source":"Crossref","is-referenced-by-count":13,"title":["Topical Resiquimod Protects against Visceral Infection with Leishmania infantum chagasi in Mice"],"prefix":"10.1128","volume":"21","author":[{"given":"Noah","family":"Craft","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ron","family":"Birnbaum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalie","family":"Quanquin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie Crisel B.","family":"Erfe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cara","family":"Quant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacquelyn","family":"Haskell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin W.","family":"Bruhn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","published-online":{"date-parts":[[2014,7,16]]},"reference":[{"key":"key20180919073744_B1","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S0035-9203(01)90223-8","article-title":"The increase in risk factors for leishmaniasis worldwide","volume":"95","author":"Desjeux","year":"2001","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"key20180919073744_B2","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1590\/S0074-02762007000500001","article-title":"The leishmaniases\u2014survival and expansion in a changing world: a minireview","volume":"102","author":"Shaw","year":"2007","journal-title":"Mem. Inst. Oswaldo Cruz"},{"key":"key20180919073744_B3","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1016\/S0140-6736(05)67629-5","article-title":"Advances in leishmaniasis","volume":"366","author":"Murray","year":"2005","journal-title":"Lancet"},{"key":"key20180919073744_B4","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/S1473-3099(10)70011-6","article-title":"Combination therapy for visceral leishmaniasis","volume":"10","author":"van","year":"2010","journal-title":"Lancet Infect. Dis."},{"key":"key20180919073744_B5","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/S0065-308X(05)61006-8","article-title":"Chemotherapy in the treatment and control of leishmaniasis","volume":"61","author":"Alvar","year":"2006","journal-title":"Adv. Parasitol."},{"key":"key20180919073744_B6","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1358\/dnp.2008.21.2.1188193","article-title":"The antiviral activity of Toll-like receptor 7 and 7\/8 agonists","volume":"21","author":"Miller","year":"2008","journal-title":"Drug News Perspect."},{"key":"key20180919073744_B7","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/S0008-8749(02)00517-8","article-title":"Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod","volume":"218","author":"Gibson","year":"2002","journal-title":"Cell. Immunol."},{"key":"key20180919073744_B8","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.2165\/00003495-200767150-00006","article-title":"Topical imiquimod: a review of its use in the management of anogenital warts, actinic keratoses, basal cell carcinoma, and other skin lesions","volume":"67","author":"Wagstaff","year":"2007","journal-title":"Drugs"},{"key":"key20180919073744_B9","doi-asserted-by":"publisher","first-page":"730","DOI":"10.2174\/1389557511313050010","article-title":"Quinolines as chemotherapeutic agents for leishmaniasis","volume":"13","author":"Reynolds","year":"2013","journal-title":"Mini. Rev. Med. Chem."},{"key":"key20180919073744_B10","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1086\/314782","article-title":"Treatment of experimental leishmaniasis with the immunomodulators imiquimod and S-28463: efficacy and mode of action","volume":"179","author":"Buates","year":"1999","journal-title":"J. Infect. Dis."},{"key":"key20180919073744_B11","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1046\/j.1365-4362.2003.01955.x","article-title":"Transient effect of topical treatment of cutaneous leishmaniasis with imiquimod","volume":"42","author":"Seeberger","year":"2003","journal-title":"Int. J. Dermatol."},{"key":"key20180919073744_B12","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1001\/archderm.142.12.1575","article-title":"Imiquimod in combination with meglumine antimoniate for cutaneous leishmaniasis: a randomized assessor-blind controlled trial","volume":"142","author":"Firooz","year":"2006","journal-title":"Arch. Dermatol."},{"key":"key20180919073744_B13","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1111\/j.1365-4632.2008.04010.x","article-title":"Tropical medicine rounds: treatment of Old World cutaneous leishmaniasis with dapsone, itraconazole, cryotherapy, and imiquimod, alone and in combination","volume":"48","author":"Al-Mutairi","year":"2009","journal-title":"Int. J. Dermatol."},{"key":"key20180919073744_B14","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.exppara.2006.12.004","article-title":"Leishmania major: in vitro and in vivo anti-leishmanial activity of paromomycin ointment (Leshcutan) combined with the immunomodulator Imiquimod","volume":"116","author":"El-On","year":"2007","journal-title":"Exp. Parasitol."},{"key":"key20180919073744_B15","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1086\/324161","article-title":"Successful treatment of drug-resistant cutaneous leishmaniasis in humans by use of imiquimod, an immunomodulator","volume":"33","author":"Arevalo","year":"2001","journal-title":"Clin. Infect. Dis."},{"key":"key20180919073744_B16","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1086\/429238","article-title":"Randomized, double-blind clinical trial of topical imiquimod 5% with parenteral meglumine antimoniate in the treatment of cutaneous leishmaniasis in Peru","volume":"40","author":"Miranda-Verastegui","year":"2005","journal-title":"Clin. Infect. Dis."},{"key":"key20180919073744_B17","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1086\/518172","article-title":"Role of imiquimod and parenteral meglumine antimoniate in the initial treatment of cutaneous leishmaniasis","volume":"44","author":"Arevalo","year":"2007","journal-title":"Clin. Infect. Dis."},{"key":"key20180919073744_B18","doi-asserted-by":"publisher","first-page":"e491","DOI":"10.1371\/journal.pntd.0000491","article-title":"First-line therapy for human cutaneous leishmaniasis in Peru using the TLR7 agonist imiquimod in combination with pentavalent antimony","volume":"3","author":"Miranda-Verastegui","year":"2009","journal-title":"PLoS Negl. Trop. Dis."},{"key":"key20180919073744_B19","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/0166-3542(95)00054-P","article-title":"Immunomodulating and antiviral activities of the imidazoquinoline S-28463","volume":"28","author":"Tomai","year":"1995","journal-title":"Antivir. Res."},{"key":"key20180919073744_B20","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1006\/cimm.1998.1406","article-title":"Modulation of TH1 and TH2 cytokine production with the immune response modifiers, R-848 and imiquimod","volume":"191","author":"Wagner","year":"1999","journal-title":"Cell. Immunol."},{"key":"key20180919073744_B21","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1046\/j.1523-1747.2000.00833.x","article-title":"Imiquimod, a topical immune response modifier, induces migration of Langerhans cells","volume":"114","author":"Suzuki","year":"2000","journal-title":"J. Invest. Dermatol."},{"key":"key20180919073744_B22","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.4049\/jimmunol.175.3.1983","article-title":"The TLR7 agonist imiquimod enhances the anti-melanoma effects of a recombinant Listeria monocytogenes vaccine","volume":"175","author":"Craft","year":"2005","journal-title":"J. Immunol."},{"key":"key20180919073744_B23","doi-asserted-by":"publisher","first-page":"5263","DOI":"10.1016\/j.vaccine.2005.06.024","article-title":"TLR agonists as vaccine adjuvants: comparison of CpG ODN and resiquimod (R-848)","volume":"23","author":"Weeratna","year":"2005","journal-title":"Vaccine"},{"key":"key20180919073744_B24","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1586\/14760584.6.5.835","article-title":"Resiquimod and other immune response modifiers as vaccine adjuvants","volume":"6","author":"Tomai","year":"2007","journal-title":"Expert Rev. Vaccines"},{"key":"key20180919073744_B25","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1128\/IAI.00974-08","article-title":"Enhanced immunogenicity of Plasmodium falciparum peptide vaccines using a topical adjuvant containing a potent synthetic Toll-like receptor 7 agonist, imiquimod","volume":"77","author":"Othoro","year":"2009","journal-title":"Infect. Immun."},{"key":"key20180919073744_B26","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1016\/j.vaccine.2009.03.018","article-title":"Intradermal immunization improves protective efficacy of a novel TB vaccine candidate","volume":"27","author":"Baldwin","year":"2009","journal-title":"Vaccine"},{"key":"key20180919073744_B27","doi-asserted-by":"publisher","first-page":"3777","DOI":"10.1128\/IAI.01527-07","article-title":"Immunization with a Toll-like receptor 7 and\/or 8 agonist vaccine adjuvant increases protective immunity against Leishmania major in BALB\/c mice","volume":"76","author":"Zhang","year":"2008","journal-title":"Infect. Immun."},{"key":"key20180919073744_B28","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00077-14","article-title":"Three phase III randomized controlled trials of topical resiquimod 0.01% gel to reduce anogenital herpes recurrences","author":"Mark","year":"2014","journal-title":"Antimicrob. Agents Chemother"},{"key":"key20180919073744_B29","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/S0169-4758(00)01637-9","article-title":"The strange case of Leishmania chagasi","volume":"16","author":"Mauricio","year":"2000","journal-title":"Parasitol. Today"},{"key":"key20180919073744_B30","doi-asserted-by":"publisher","first-page":"360","DOI":"10.2307\/3279142","article-title":"A simple monophasic medium for axenic culture of hemoflagellates","volume":"62","author":"Berens","year":"1976","journal-title":"J. Parasitol."},{"key":"key20180919073744_B31","first-page":"119","article-title":"Regulation of Leishmania populations within the host. I. the variable course of Leishmania donovani infections in mice","volume":"30","author":"Bradley","year":"1977","journal-title":"Clin. Exp. Immunol."},{"key":"key20180919073744_B32","doi-asserted-by":"publisher","first-page":"e886","DOI":"10.1371\/journal.pntd.0000886","article-title":"LXR deficiency confers increased protection against visceral Leishmania infection in mice","volume":"4","author":"Bruhn","year":"2010","journal-title":"PLoS Negl. Trop. Dis."},{"key":"key20180919073744_B33","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1586\/14760584.2013.811208","article-title":"The use of Toll-like receptor 7\/8 agonists as vaccine adjuvants","volume":"12","author":"Vasilakos","year":"2013","journal-title":"Expert Rev. Vaccines"},{"key":"key20180919073744_B34","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.4049\/jimmunol.166.3.1921","article-title":"Protective immunity against the protozoan Leishmania chagasi is induced by subclinical cutaneous infection with virulent but not avirulent organisms","volume":"166","author":"Streit","year":"2001","journal-title":"J. Immunol."},{"key":"key20180919073744_B35","doi-asserted-by":"publisher","first-page":"3846","DOI":"10.1128\/AAC.47.12.3846-3852.2003","article-title":"Randomized, single-blind, placebo-controlled study of topical application of the immune response modulator resiquimod in healthy adults","volume":"47","author":"Sauder","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"key20180919073744_B36","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1182\/blood-2008-04-151712","article-title":"Triggering TLR7 in mice induces immune activation and lymphoid system disruption, resembling HIV-mediated pathology","volume":"113","author":"Baenziger","year":"2009","journal-title":"Blood"},{"key":"key20180919073744_B37","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1093\/jac\/dkt320","article-title":"Liposomal resiquimod for the treatment of Leishmania donovani infection","volume":"69","author":"Peine","year":"2014","journal-title":"J. Antimicrob. Chemother."},{"key":"key20180919073744_B38","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1021\/mp3005098","article-title":"Electrospray encapsulation of Toll-like receptor agonist resiquimod in polymer microparticles for the treatment of visceral leishmaniasis","volume":"10","author":"Duong","year":"2013","journal-title":"Mol. Pharm."},{"key":"key20180919073744_B39","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1038\/ni758","article-title":"Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway","volume":"3","author":"Hemmi","year":"2002","journal-title":"Nat. Immunol."},{"key":"key20180919073744_B40","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/ni0602-499","article-title":"Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848","volume":"3","author":"Jurk","year":"2002","journal-title":"Nat. Immunol."},{"key":"key20180919073744_B41","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1089\/jir.1996.16.555","article-title":"Effect of a novel topical immunomodulator, S-28463, on keratinocyte cytokine gene expression and production","volume":"16","author":"Fujisawa","year":"1996","journal-title":"J. Interferon Cytokine Res."},{"key":"key20180919073744_B42","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1084\/jem.20020207","article-title":"Interferon-alpha and interleukin-12 are induced differentially by Toll-like receptor 7 ligands in human blood dendritic cell subsets","volume":"195","author":"Ito","year":"2002","journal-title":"J. Exp. Med."},{"key":"key20180919073744_B43","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1006\/cimm.2000.1673","article-title":"The immune response modifiers imiquimod and R-848 are potent activators of B lymphocytes","volume":"203","author":"Tomai","year":"2000","journal-title":"Cell. Immunol."},{"key":"key20180919073744_B44","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1046\/j.1365-2230.2002.01151.x","article-title":"Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential","volume":"27","author":"Stanley","year":"2002","journal-title":"Clin. Exp. Dermatol."},{"key":"key20180919073744_B45","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1126\/science.8009221","article-title":"Functional role of type I and type II interferons in antiviral defense","volume":"264","author":"Muller","year":"1994","journal-title":"Science"},{"key":"key20180919073744_B46","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1126\/science.1074900","article-title":"Critical role for STAT4 activation by type 1 interferons in the interferon-gamma response to viral infection","volume":"297","author":"Nguyen","year":"2002","journal-title":"Science"},{"key":"key20180919073744_B47","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.4049\/jimmunol.169.4.1665","article-title":"Cutting edge: a murine, IL-12-independent pathway of IFN-gamma induction by gram-negative bacteria based on STAT4 activation by type I IFN and IL-18 signaling","volume":"169","author":"Freudenberg","year":"2002","journal-title":"J. Immunol."},{"key":"key20180919073744_B48","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1006\/expr.1996.0099","article-title":"Leishmania major: differential resistance to infection in C57BL\/6 (high interferon-alpha\/beta) and congenic B6.C-H-28c (low interferon-alpha\/beta) mice","volume":"84","author":"Shankar","year":"1996","journal-title":"Exp. Parasitol."},{"key":"key20180919073744_B49","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S1074-7613(00)80460-4","article-title":"Type 1 interferon (IFN\u03b1\/\u03b2) and type 2 nitric oxide synthase regulate the innate immune response to a protozoan parasite","volume":"8","author":"Diefenbach","year":"1998","journal-title":"Immunity"},{"key":"key20180919073744_B50","doi-asserted-by":"publisher","first-page":"7574","DOI":"10.4049\/jimmunol.172.12.7574","article-title":"Protection against progressive leishmaniasis by IFN-\u03b2","volume":"172","author":"Mattner","year":"2004","journal-title":"J. Immunol."},{"key":"key20180919073744_B51","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1586\/eri.10.64","article-title":"Immunomodulators: use in combined therapy against leishmaniasis","volume":"8","author":"Dalton","year":"2010","journal-title":"Expert Rev. Anti Infect. Ther."}],"container-title":["Clinical and Vaccine Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1128\/CVI.00338-14","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T20:51:09Z","timestamp":1627591869000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/CVI.00338-14"}},"subtitle":[],"editor":[{"given":"P. P.","family":"Wilkins","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2014,7,16]]},"references-count":51,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2014,8,28]]},"published-print":{"date-parts":[[2014,9]]}},"alternative-id":["10.1128\/CVI.00338-14"],"URL":"https:\/\/doi.org\/10.1128\/cvi.00338-14","relation":{},"ISSN":["1556-6811","1556-679X"],"issn-type":[{"value":"1556-6811","type":"print"},{"value":"1556-679X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,7,16]]}}}